header
Image from OpenLibrary

Effect of anti-epileptic drug (oxcarbazepine) on albino rat fetuses and offspring during pregnancy and lactation / Rania Yahia Kamel ; Supervsied Abdelwahab Elghareeb , Hamida Hamdi Mohamed , Osama Mohammed Ahmed

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Rania Yahia Kamel , 2016Description: 144 P. : facsimiles ; 25cmOther title:
  • تأثير عقار الاوكسكاربازبين المضاد للصرع على أجنة وولائد الجرذان البيضاء أثناء الحمل و الرضاعة [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (Ph.D.) - Cairo University - Faculty of Science - Department of Zoology Summary: The use of the older generation antiepileptic drugs (AEDs) during pregnancy and lactation is known to be associated with increased risk of birth defects in the offspring. Much less has been known about newer generation AEDs to which oxcarbazepine (OXC) belongs. OXC is abroad spectrum antiepileptic drug which is currently licensed worldwide. The aim of this study was to evaluate the teratogenic effects of oxcarbazepine on fetuses and neonates of albino rats. Pregnant albino rats (Rattusnorvegicus) were administrated daily oral dose of 108mg/kg from the 7th day of gestation till end of lactation. The animals were sacrificed at 20th day of gestation and during lactation. Fetuses were removed from the uterus and evaluated for mortality rate, growth parameters, morphological and skeletal malformations as well as histological study of brain, liver and kidney. The data revealed that fetal and neonatal weights were not significantly reduced in the treated groups. Resorption rates were significantly increased. It was found that mild degenerative changes were observed in the liver, kidney as well as the brain following OXC administration. Biochemical studies showed that Fetuses and neonates exposed to 108 mg/kg oxcarbazepine showed no significant reduction in the level GSH and catalase compared to control group. Thus administration of OXC during pregnancy and lactation should only be considered if the expected benefit to the mother is greater than any possible risk to the fetus
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Date due Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.12.21.Ph.D.2016.Ra.E (Browse shelf(Opens below)) Not for loan 01010110072098000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.12.21.Ph.D.2016.Ra.E (Browse shelf(Opens below)) 72098.CD Not for loan 01020110072098000

Thesis (Ph.D.) - Cairo University - Faculty of Science - Department of Zoology

The use of the older generation antiepileptic drugs (AEDs) during pregnancy and lactation is known to be associated with increased risk of birth defects in the offspring. Much less has been known about newer generation AEDs to which oxcarbazepine (OXC) belongs. OXC is abroad spectrum antiepileptic drug which is currently licensed worldwide. The aim of this study was to evaluate the teratogenic effects of oxcarbazepine on fetuses and neonates of albino rats. Pregnant albino rats (Rattusnorvegicus) were administrated daily oral dose of 108mg/kg from the 7th day of gestation till end of lactation. The animals were sacrificed at 20th day of gestation and during lactation. Fetuses were removed from the uterus and evaluated for mortality rate, growth parameters, morphological and skeletal malformations as well as histological study of brain, liver and kidney. The data revealed that fetal and neonatal weights were not significantly reduced in the treated groups. Resorption rates were significantly increased. It was found that mild degenerative changes were observed in the liver, kidney as well as the brain following OXC administration. Biochemical studies showed that Fetuses and neonates exposed to 108 mg/kg oxcarbazepine showed no significant reduction in the level GSH and catalase compared to control group. Thus administration of OXC during pregnancy and lactation should only be considered if the expected benefit to the mother is greater than any possible risk to the fetus

Issued also as CD

There are no comments on this title.

to post a comment.